🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy

Recruitingn/aAges 18 Years - anyMaleUniversity of Erlangen-Nürnberg Medical School
NCT07131956 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria Arm 1: * Primary treatment with I-125 seeds or HDR-BT * No previous treatment for prostate cancer * Age ≥ 18 years Inclusion Criteria Arm 2: * HDR- or PDR-BT * No radiation therapy within three months before salvage treatment * Complete documentation available on previous treatment for prostate cancer * No history of prostatectomy * Age ≥ 18 years Exclusion Criteria: * Pre-existent auto-immune disease * patients under bloodthinning medication * substance abuse
💊

What it tests

  • Not listed
📍

Where

3 sites
Klinik für Strahlentherapie
Augsburg, Germany
Strahlenklinik Erlangen
Erlangen, Germany
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
Munich, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy